[Evaluation of postoperative immunochemotherapy of lung cancer].
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001688:Biological Products / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010844:Picibanil / Q000627:therapeutic use*; D011184:Postoperative Period; D011379:Prognosis; D011509:Proteoglycans / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D001688:Biological Products; D011509:Proteoglycans; D010844:Picibanil; C010770:polysaccharide-K